Evidence map›Paper›PMID 37932634›Full record

ArticleActa neurochirurgica2023

Moyamoya disease presenting with symptomatic ischemic stroke during new-generation tyrosine kinase inhibitor treatment: two illustrative cases.

Hideki Nakajima, Ryota Miyake, Taku Hongo, Morio Takasaki, Yasuhiro Fujimoto, Katsuhiro Io

Abstract read
PubMed Publisher
In one paragraph

Article in Acta neurochirurgica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Hideki NakajimaDepartment of Neurosurgery, Kansai Electric Power Hospital, 2-1-7 Fukushima, Fukushima-Ku, Osaka, 553-0003, Japan. hikkinakajima@yahoo.co.jp.
Ryota MiyakeDepartment of Neurosurgery, Kansai Electric Power Hospital, 2-1-7 Fukushima, Fukushima-Ku, Osaka, 553-0003, Japan.
Taku HongoDepartment of Neurosurgery, Kansai Electric Power Hospital, 2-1-7 Fukushima, Fukushima-Ku, Osaka, 553-0003, Japan.
Morio TakasakiDepartment of Neurosurgery, Kansai Electric Power Hospital, 2-1-7 Fukushima, Fukushima-Ku, Osaka, 553-0003, Japan.
Yasuhiro FujimotoDepartment of Neurosurgery, Kansai Electric Power Hospital, 2-1-7 Fukushima, Fukushima-Ku, Osaka, 553-0003, Japan.
Katsuhiro IoDepartment of Hematology, Kansai Electric Power Hospital, Osaka, Japan.
Kansai Electric Power Hospital · JPKansai Electric Power (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tyrosine kinase inhibitors (TKIs) have been widely used to treat chronic myeloid leukemia. Nilotinib and ponatinib, which are second- and third-generation TKIs, have been reported to cause cerebrovascular arterial complications. Here, we present two cases of moyamoya disease presenting with symptomatic ischemic stroke during new-generation TKI treatment. We judged that new-generation TKI treatment was a factor in symptomatic ischemic stroke of unknown moyamoya disease in both cases. Noninvasive examinations using magnetic resonance imaging or carotid ultrasonography should be performed before and during new-generation TKI treatment in order to prevent symptomatic ischemic stroke.

Indexed as

Antineoplastic AgentsIschemic StrokeMoyamoya DiseaseHumansProtein Kinase InhibitorsTyrosine Kinase InhibitorsAntineoplastic AgentsProtein Kinase InhibitorsTyrosine Kinase InhibitorsCerebrovascular stenosisChronic myeloid leukemiaMoyamoya diseaseTyrosine kinase inhibitor

Identifiers

PMID37932634
OpenAlexW4388408090

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.